Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 21:14:1162665.
doi: 10.3389/fphar.2023.1162665. eCollection 2023.

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future

Brigida Anna Maiorano  1   2 , Mauro Francesco Pio Maiorano  3 , Evaristo Maiello  1
Affiliations
Review

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future

Brigida Anna Maiorano et al. Front Pharmacol. .

Abstract

Ovarian cancer (OC) is women's eighth most common cancer, bearing the highest mortality rates of all female reproductive system malignancies. Poly (ADP-ribose) polymerase inhibitors (PARPis) have reshaped the treatment scenario of metastatic OC as a maintenance post platinum-based chemotherapy. Olaparib is the first PARPi developed for this disease. Results from Study 42, Study 19, SOLO2, OPINION, SOLO1, and PAOLA-1 clinical trials, led to the FDA and EMA approval of olaparib for the maintenance treatment of women with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer without platinum progression: in the platinum-sensitive recurrent OC; in the newly diagnosed setting in case Breast Cancer (BRCA) mutations and, in combination with bevacizumab, in case of BRCA mutation or deficiency of homologous recombination genes. In this review, we synthetized olaparib's pharmacokinetic and pharmacodynamic properties and its use in special populations. We summarized the efficacy and safety of the studies leading to the current approvals and discussed the future developments of this agent.

Keywords: BRCA; PARP; olaparib (LynparzaTM); ovarian cancer; target therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Most frequent all-grades adverse events during olaparib therapy.
FIGURE 2
FIGURE 2
Most frequent ≥G3 adverse events during olaparib therapy.
See this image and copyright information in PMC

References

    1. Adams S. F., Rixe O., Lee J. H., McCance D. J., Westgate S., Eberhardt S. C., et al. (2017). Phase I study combining olaparib and tremelimumab for the treatment of women with BRCA-deficient recurrent ovarian cancer. JCO 35, e17052. 10.1200/JCO.2017.35.15_suppl.e17052 - DOI
    1. Ang J. E., Clarkson-Jones J. A., Swaisland H., Brunetto A. T., Lal R., Farnsworth A. P., et al. (2010). 405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments. Eur. J. Cancer Suppl. 8, 128–129. 10.1016/S1359-6349(10)72112-1 - DOI
    1. Ang J. E., Gourley C., Powell C. B., High H., Shapira-Frommer R., Castonguay V., et al. (2013). Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: A multi-institutional study. Clin. Cancer Res. 19, 5485–5493. 10.1158/1078-0432.CCR-13-1262 - DOI - PubMed
    1. Armstrong D. K., Bundy B., Wenzel L., Huang H. Q., Baergen R., Lele S., et al. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34–43. 10.1056/NEJMoa052985 - DOI - PubMed
    1. Arora S., Balasubramaniam S., Zhang H., Berman T., Narayan P., Suzman D., et al. (2021). FDA approval summary: Olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer. Oncol. 26, e164–e172. 10.1002/onco.13551 - DOI - PMC - PubMed